Key takeaways:

• Nufymco is indicated for the treatment of patients with a number of retinal diseases.
• The VEGF inhibitor is the second approved ranibizumab biosimilar in the U.S. from Formycon and Bioeq.

The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar in the U.S. from Formycon and Bioeq, the companies announced in a press release.

Additionally, Zydus Lifesciences Global FZE has entered a strategic partnership with Bioeq. Under the terms of the agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the biosimilar, while Zydus will control its commercialization in the U.S. market.

Nufymco is indicated for the treatment of patients with a number of retinal diseases.

Nufymco (ranibizumab-leyk), a VEGF inhibitor, is indicated for the treatment of retinal diseases including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema due to retinal vein occlusion and myopic choroidal neovascularization.

Read more:https://www.healio.com/news/ophthalmology/20251223/fda-approves-nufymco-as-biosimilar-to-lucentis?utm_source=selligent&utm_medium=email&utm_campaign=20251229PCON&utm_content=20251229PCON

Source: Healio